Loading...
mevalonate pathway→apoptosis induction→anticancer effect enhancement
Statins demonstrate anticancer activity against cholangiocarcinoma through mevalonate pathway inhibition, induction of apoptosis, and potential enhancement of anticancer drug efficacy. Evidence includes meta-analyses of observational studies confirming reduced incidence and clinical studies suggesting treatment benefit. This is a researcher-prioritized domain with meaningful epidemiological and mechanistic support.
“Clinical studies, supported by meta-analysis, confirm that statins are highly effective in preventing and treating hepatocellular carcinoma and cholangiocarcinoma.”
— Don't Judge a Book by Its Cover: The Role of Statins in Liver Cancer. (2023)DOI“Together, these results suggest that statins may be a new cholangiocarcinoma treatment option that could potentially enhance the anticancer effect of pre-existing anticancer drugs.”
— Statins induce apoptosis and inhibit proliferation in cholangiocarcinoma cells. (2011)DOI“Sa338 STATINS ARE ASSOCIATED WITH REDUCED INCIDENCE OF CHOLANGIOCARCINOMA: SYSTEMATIC REVIEW AND META-ANALYSIS OF OBSERVATIONAL STUDIES.”
— Sa338 STATINS ARE ASSOCIATED WITH REDUCED INCIDENCE OF CHOLANGIOCARCINOMA: SYSTEMATIC REVIEW AND META-ANALYSIS OF OBSERVATIONAL STUDIES. (2021)DOI“The use of statins has been shown to be associated with a decreased risk of cholangiocarcinoma (CCA) in many studies although the results have been inconsistent.”
— Statins and Risk of Cholangiocarcinoma: A Systematic Review and Meta-analysis. (2020)DOI“Hydroxy-methyl-glutaryl-coenzyme A reductase inhibitors (statins) reportedly exert anti-cancer effects in CCA and lower the risk of CCA; however, the underlying mechanism of these effects remains unclear.”
— Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells. (2020)DOI“In view of the enhanced malignancy risk, statins, and aspirin show potential for reducing the risk of colorectal cancer and cholangiocarcinoma in PSC patients.”
— Current Therapeutics in Primary Sclerosing Cholangitis. (2023)DOI“Conclusions Our study shows statistically significant association between the use of statins and 0.79-fold decreased risk of CCA.”
— Statin use decreases the risk of cholangiocarcinoma: A meta-analysis. (2021)DOI